Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART with Spiromax budesonide/formoterol versus fixed-dose Diskus fluticasone/salmeterol in COPD
2014-001563-12Phase 3Active
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of budesonide + formoterol, salmeterol + fluticasone, budesonide, formoterol, fluticasone and 1 more in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Number of COPD exacerbations. Started Feb 2015; status: active.
02
Drugs
budesonide + formoterolsalmeterol + fluticasonebudesonideformoterolfluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-001563-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001563-12.